Physician profile
Dandan Chen
NPI 1477973808
$4,422.40
in general payments reported to CMS, 2019-2025
33 companies · $871 in 2025
The $871 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $96.11 · 2022: $1,297 · 2023: $668 · 2024: $1,491 · 2025: $871.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,029.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,029.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $611.18 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $370.45 | 2023-2025 | Verquvo, Winrevair, Capvaxive |
| Novartis Pharmaceuticals Corporation | $365.52 | 2022-2025 | |
| Actelion Pharmaceuticals US, INC. | $325.72 | 2021-2025 | Uptravi, Opsumit, Opsynvi |
| Astrazeneca Pharmaceuticals Lp | $309.52 | 2022-2024 | Airsupra, Andexxa, Farxiga |
| Penumbra, INC. | $298.80 | 2024 | Indigo System |
| Abbott Laboratories | $197.94 | 2022-2024 | Mitraclip |
| Cvrx, INC. | $186.46 | 2022-2023 | Barostim Neo System |
| Astellas Pharma US INC | $151.98 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $125.00 | 2024 | |
| Calliditas Therapeutics US INC. | $125.00 | 2024 | |
| Heartflow, INC. | $119.67 | 2022 | |
| Abbvie INC. | $117.19 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $115.41 | 2023-2025 | Jardiance |
| Impel Pharmaceuticals INC. | $114.92 | 2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $97.29 | 2021-2025 | Nexletol |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $95.29 | 2024-2025 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $83.41 | 2024-2025 | Camzyos, Eliquis |
| Amgen INC. | $80.67 | 2022-2023 | Repatha |
| Edwards Lifesciences Corporation | $75.47 | 2023-2024 | Edwards Sapien 3 Ultra Transcatheter Heart Valve, Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Bridgebio Pharma, INC. | $72.53 | 2025 | Attruby |
| Abiomed | $53.44 | 2021-2025 | |
| Amarin Pharma, INC. | $46.61 | 2021-2022 | |
| Boston Scientific Corporation | $43.93 | 2024-2025 | Bodyguardian, Varithena Administration Pack |
| Emd Serono, INC. | $41.25 | 2023 | Mavenclad |
| Angiodynamics, INC. | $39.38 | 2024 | Alphavac |
| Janssen Pharmaceuticals, INC | $36.72 | 2023-2024 | Xarelto |
| Vital Connect, INC | $29.16 | 2024 | Vitalpatch Rtm |
| Alnylam Pharmaceuticals INC. | $27.39 | 2022 | |
| Lexicon Pharmaceuticals, INC. | $18.62 | 2023 | Inpefa |
| Kiniksa Pharmaceuticals International, Plc | $18.39 | 2024 | Arcalyst |
| Impulse Dynamics (USA) INC. | $15.82 | 2023 | Optimizer |
| G Medical Diagnostic Services, INC. | $12.27 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dandan Chen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.